GENinCode (LON:GENI) Trading 9.4% Higher – Here’s What Happened

GENinCode Plc (LON:GENI)’s stock price traded up 9.4% on Thursday . The company traded as high as GBX 0.90 and last traded at GBX 0.88. 7,631,066 shares were traded during mid-day trading, an increase of 31% from the average daily volume of 5,831,207 shares. The stock had previously closed at GBX 0.80.

GENinCode Stock Performance

The company has a current ratio of 0.93, a quick ratio of 15.88 and a debt-to-equity ratio of 117.74. The company’s 50 day moving average is GBX 0.95 and its 200-day moving average is GBX 1.15. The company has a market capitalization of £6.02 million, a P/E ratio of -0.38 and a beta of 0.59.

GENinCode (LON:GENI) last issued its quarterly earnings results on Monday, June 8th. The company reported GBX (2.08) earnings per share (EPS) for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. The business had revenue of GBX 308 million for the quarter. Equities analysts anticipate that GENinCode Plc will post -7.1299999 EPS for the current fiscal year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.